Search

Your search keyword '"Colella E."' showing total 167 results
Start Over Author "Colella E."
167 results on '"Colella E."'

1. Measurements of Reconfigurable Intelligent Surface in 5G System Within a Reverberation Chamber at mmWave

Author

Bastianelli, L., Diamanti, R., Colella, E., Primiani, V. Mariani, Moglie, F., Toubal, M. A., Odit, M., Gros, J. -B., Nasser, Y., Lerosey, G., Santamaria, L., Allasia, A., Crozzoli, M., Boldi, M., Zimaglia, E., Lieti, V., Colombo, M., and Micheli, D.

Subjects
Physics - Applied Physics
Abstract

In this paper we evaluated the performance of a reconfigurable intelligent surface tested with a fifth generation signal provided by a commercial fifth generation base station. We adopted a reverberation chamber as a real life propagating environment. Tests were conducted at the millimeter wave frequency range. This measurement campaign was carried out under the H2020 European project RISE-6G and a collaboration program between TIM S.p.A., Nokia and Universit\`a Politecnica delle Marche., Comment: Accepted at EuCAP 2024

Published
2023

3. An Uneasy Alliance in the Battle of the Absolute: William James and George Holmes Howison

Author

Paul Colella, E.

Subjects
The Correspondence of William James (Letter Collection), Philosophy, Philosophy and religion
Abstract

The closing section of James's 'Philosophical Conceptions and Practical Results' contains a surprisingly abrupt dismissal of Kant's philosophy. This paper suggests that James's real target is his host, George Holmes Howison, whose Philosophical Union had invited James to speak at Berkeley. James and Howison shared a common commitment to pluralism in opposition to the Absolute monism such as Josiah Royce was developing. Howison relies on Kant's account of the a priori as well as his moral ideal of a Kingdom of Ends in order to fashion a pluralistic form of |idealism that would avoid the errors he found in Absolute monism while also countering the influential evolutionary philosophy of Herbert Spencer. While James shared Howison's opposition to monism, as well as his critical view of Spencer, he did not share his aversion to evolutionary ideas. Ultimately, the pragmatism that he announced at Berkeley would reply to Howison's Kantian approach by retaining a pluralism while building on the modern psychology growing out of evolution. James's position would test the alliance that they had forged against monism. In time, it would prove too fragile to withstand their growing differences until a final break came in the year before James's death. Keywords: William James, George Howison, pluralism, idealism, pragmatism, evolution, When William James arrived to address a California audience in August 1898, the America of 1900 a mere year and a half away. The transition from the old century to [...]

Published
2023
Full Text
View/download PDF

4. Quantum phases of spinful Fermi gases in optical cavities

Author

Colella, E., Citro, R., Barsanti, M., Rossini, D., and Chiofalo, M. L.

Subjects
Condensed Matter - Quantum Gases
Abstract

We explore the quantum phases emerging from the interplay between spin and motional degrees of freedom of a one-dimensional quantum fluid of spinful fermionic atoms, effectively interacting via a photon-mediating mechanism with tunable sign and strength g, as it can be realized in present-day experiments with optical cavities. We find the emergence, in the very same system, of spin- and atomic-density wave ordering, accompanied by the occurrence of superfluidity for g > 0, while cavity photons are seen to drive strong correlations at all g values, with fermionic character for g > 0, and bosonic character for g < 0. Due to the long-range nature of interactions, to infer these results we combine mean-field and exact diagonalization methods supported by bosonization analysis., Comment: 9 pages, 4 figures. Published version

Published
2017
Full Text
View/download PDF

6. HIV and SARS-CoV-2 Co-Infection: What are the Risks?

Author

Squillace N, Ricci E, Colella E, and Bonfanti P

Subjects
hiv, sars-cov-2, covid-19, Infectious and parasitic diseases, RC109-216
Abstract

Nicola Squillace,1 Elena Ricci,2 Elisa Colella,1 Paolo Bonfanti1 1Infectious Diseases Unit ASST-Monza, San Gerardo Hospital-University of Milano-Bicocca, Monza, Italy; 2Fondazione ASIA Onlus, Milan, ItalyCorrespondence: Nicola SquillaceInfectious Diseases Unit ASST-Monza, San Gerardo Hospital-University of Milano-Bicocca, via G.B. Pergolesi 33, Monza, 20900, ItalyEmail n.squillace@asst-monza.it; nicolasquillace74@gmail.comAbstract: The dramatic increase of the global pandemic of SARS-CoV-2 infection represents a critical issue that needs to be investigated to evaluate the associated risk factors for acquisition and worse outcome. The interplay between immune activation and immune depression during SARS-CoV-2 infection is an intriguing topic that still needs to be clarified. The role of HIV in SARS-CoV-2 infection is not well defined. Chronic inflammation linked to HIV infection could be a driver for a worse prognosis in people living with HIV (PLWH). We explored the role of HIV as a risk factor for SARS-CoV-2 infection and severity and which factors contributed to a worse prognosis when HIV infection was present. PubMed/MEDLINE was searched for “COVID-19” or “SARS-CoV2” and “HIV” or “AIDS” and (“hospitalization” or “intensive care” or “mechanical ventilation” or “death” OR “mortality”), both in MeSH and as free text in all fields. Our review focused on 21 studies that enrolled at least 40 PLWH. In most studies, HIV infection did not represent a risk factor for SARS-CoV-2 infection. On the contrary, the risk of severe COVID-19 and hospitalization was higher in PLWH. Low CD4 cell count consistently emerged as a risk factor for severe COVID-19. Comorbidities, either in people with or without HIV diagnosis, played a key role, especially because of their early development in PLWH.Keywords: HIV, SARS, CoV-2, COVID-19

Published
2021

7. High-risk HPV genotypes are associated with anal cytologic abnormalities but not with malignant histological lesions in a cohort of people with HIV (PWH)

Author

Squillace, N, Bernasconi, D, Cogliandro, V, Lapadula, G, Soria, A, Sabbatini, F, Colella, E, Rossi, M, Cappelletti, A, Spreafico, G, Tamburini, A, Leone, B, Malandrin, S, Cavallero, A, Di Lucia, A, Braga, M, Bonfanti, P, Bernasconi, DP, Tamburini, AM, Leone, BE, Squillace, N, Bernasconi, D, Cogliandro, V, Lapadula, G, Soria, A, Sabbatini, F, Colella, E, Rossi, M, Cappelletti, A, Spreafico, G, Tamburini, A, Leone, B, Malandrin, S, Cavallero, A, Di Lucia, A, Braga, M, Bonfanti, P, Bernasconi, DP, Tamburini, AM, and Leone, BE

Published
2024

8. Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era

Author

Squillace N, Bozzi G, Colella E, Gori A, and Bandera A

Subjects
Protease inhibitors, darunavir/cobicistat, emtricitabine/tenofovir alafenamide, HIV, Therapeutics. Pharmacology, RM1-950
Abstract

Nicola Squillace,1 Giorgio Bozzi,2 Elisa Colella,1 Andrea Gori,2 Alessandra Bandera1 1Infectious Diseases Unit, Azienda Socio Sanitaria Territoriale di Monza, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy; 2Infectious Disease Unit, Department of Internal Medicine, Fondazione IRCCS Ca’Granda, Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation, University of Milano, Milan, Italy Abstract: A fixed-dose combination consisting of darunavir (Drv), cobicistat (Cobi), emtricitabine (2',3'-dideoxy-5-fluoro-3'-thiacytidine [FTC]), and tenofovir alafenamide (Taf) has been recently approved by the European Medicines Agency for the treatment of HIV infection, and is the first ever protease-inhibitor-based single-tablet regimen. This article provides a detailed description of its pharmacokinetic, efficacy, and safety profile. The pharmacokinetics of single compounds were analyzed, with a special focus on contrasts between Drv/Cobi and Drv/ritonavir (Rtv). When comparing Cobi and Rtv, multiple interactions must be taken into account: in comparison to Rtv, Cobi is a more selective CYP3A4 inhibitor and has no clinical effect on other isoenzymes inhibited by Rtv (eg, 2C8 and 2C9). Moreover, unlike Cobi, Rtv shows in vivo induction activity on some CYP isoenzymes (eg, 1A2, 2C19, 2C8, 2C9, and 2B6), glucuronyltransferases (eg, UGT1A4), and Pgp. Drv-Cobi-FTC-Taf has recently been demonstrated to be of equal efficacy to Drv-Rtv and other protease inhibitors in both experienced (EMERALD study) and naïve (AMBER study) patients. Moreover, kidney and bone safety profiles have been shown to be good, as has central nervous system tolerance. Total cholesterol:low-density-lipoprotein cholesterol and total cholesterol:high-density-lipoprotein cholesterol ratios are generally high in Drv-Cobi-FTC-Taf vs Rtv-Drv-FTC + tenofovir disoproxil fumarate. An unlikely role of Drv in influencing cardiovascular risk in HIV infection has also been reported. Kidney safety profile is influenced by Cobi, with an increase in creatinine plasma concentration of 0.05–0.1 mg/dL and a parallel glomerular filtration-rate reduction of 10 mL/min within the first 4 weeks after Cobi introduction, which remains stable during treatment. Bone and central nervous system safety profiles were found to be good in randomized clinical trials of both experienced and naïve patients. The efficacy and safety of Drv/Cobi/FTC/Taf are comparable to other drug regimens recommended for HIV treatment. Keywords: protease inhibitors, darunavir/cobicistat, emtricitabine/tenofovir alafenamide, HIV

Published
2018

9. Hepatocellular Carcinoma in HIV-Infected Patients: Clinical Presentation and Outcomes

Author

Alimenti, E., primary, Monti, B., additional, Peracchi, F., additional, Fava, M., additional, Colella, E., additional, Columpsi, P., additional, Squillace, N., additional, Lapadula, G., additional, Lampertico, P., additional, Puoti, M., additional, Bonfanti, P., additional, Merli, M., additional, Soria, A., additional, De Silvestri, A., additional, and Iavarone, M., additional

Published
2023
Full Text
View/download PDF

13. Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study

Author

Antinori A, Meraviglia P, d’Arminio Monforte A, Castagna A, Mussini C, Bini T, Gianotti N, Rusconi S, Colella E, Airoldi G, Mancusi D, and Termini R

Subjects
darunavir/ritonavir, observational, efficacy, durability, safety, Therapeutics. Pharmacology, RM1-950
Abstract

Andrea Antinori,1 Paola Meraviglia,2 Antonella d’Arminio Monforte,3,4 Antonella Castagna,5,6 Cristina Mussini,7 Teresa Bini,4 Nicola Gianotti,5 Stefano Rusconi,8 Elisa Colella,8 Giuseppe Airoldi,9 Daniela Mancusi,10 Roberta Termini10 1Clinical Department, National Institute for Infectious Diseases “L. Spallanzani”, Rome, 2Department of Infectious Disease, “L. Sacco” University Hospital, 3Department of Health Sciences – University of Milan, 4Clinic of Infectious Diseases, “San Paolo” Hospital, 5Infectious Diseases, San Raffaele Scientific Institute, 6Università Vita-Salute San Raffaele, Milan, 7Institute of Infectious Diseases, University of Modena and Reggio Emilia, Modena, 8Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, 9Studio Associato Airoldi, Cicogna, Ghirri, 10Janssen-Cilag SpA, Medical Affairs, Cologno Monzese, Milan, Italy Abstract: Current antiretroviral (ARV) therapy for the treatment of human immunodeficiency virus (HIV-1)-infected patients provides long-term control of viral load (VL). Darunavir (DRV) is a nonpeptidomimetic protease inhibitor approved for use with a ritonavir booster (DRV/r). This study evaluated the effectiveness of DRV/r in combination with other ARV agents in routine clinical practice in Italy. In this descriptive observational study, data on utilization of DRV/r, under the conditions described in the marketing authorization, were collected from June 2009 to December 2012. Effectiveness (VL

Published
2016

15. High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting

Author

Fabbiani, M, Lombardi, A, Colaneri, M, Del Poggio, P, Perini, P, D'Ambrosio, R, Degasperi, E, Dibenedetto, C, Giorgini, A, Pasulo, L, Maggiolo, F, Castelli, F, Brambilla, P, Spinelli, O, Re, T, Lleo, A, Rumi, M, Uberti-Foppa, C, Soria, A, Aghemo, A, Lampertico, P, Baiguera, C, Schiavini, M, Fagiuoli, S, Bruno, R, Borghi, M, Soffredini, R, Perbellini, R, Gori, A, Ferroni, V, Colpani, M, Manini, M, Cologni, G, Lazzaroni, S, Vinci, M, De Nicola, S, Mazzarelli, C, Angelini Zucchetti, T, Picciotto, V, Puoti, M, Rossotti, R, Landonio, S, Magni, C, Rizzardini, G, Colella, E, Columpsi, P, Gambaro, A, Spolti, A, Magnani, C, Vigano, P, Mena, M, Villa, M, Caramma, I, Basilico, C, Capelli, F, Biagiotti, S, Mazzone, A, Saladino, V, Baldacci, M, Gatti, F, Varalli, L, Morini, L, Menzaghi, B, Farinazzo, M, Meli, R, Plaz Torres, M, Fanetti, I, Orellana, D, Zermiani, P, Zuin, M, De Bona, A, D'Arminio Monforte, A, Capretti, A, Taddei, M, Soncini, M, Spinetti, A, Zaltron, S, Pigozzi, M, Rossini, A, Pan, A, Dal Zoppo, S, Zoncada, A, Memoli, M, Salpietro, S, Hamid, H, Messina, E, Colombo, A, Giglio, O, Bonfanti, P, Molteni, C, Terreni, N, Spinzi, G, Conforti, S, Clerici, E, Menozzi, F, Buscarini, E, Centenaro, R, Corbellini, A, Noventa, F, Gritti, S, Giani, P, Fabbiani M., Lombardi A., Colaneri M., Del Poggio P., Perini P., D'Ambrosio R., Degasperi E., Dibenedetto C., Giorgini A., Pasulo L., Maggiolo F., Castelli F., Brambilla P., Spinelli O., Re T., Lleo A., Rumi M., Uberti-Foppa C., Soria A., Aghemo A., Lampertico P., Baiguera C., Schiavini M., Fagiuoli S., Bruno R., Borghi M., Soffredini R., Perbellini R., Gori A., Ferroni V., Colpani M., Manini M., Cologni G., Lazzaroni S., Vinci M., De Nicola S., Mazzarelli C., Angelini Zucchetti T., Picciotto V., Puoti M., Rossotti R., Landonio S., Magni C. F., Rizzardini G., Colella E., Columpsi P., Gambaro A., Spolti A., Magnani C., Vigano P., Mena M., Villa M., Caramma I., Basilico C., Capelli F., Biagiotti S., Mazzone A., Saladino V., Baldacci M. P., Gatti F., Varalli L., Morini L., Menzaghi B., Farinazzo M., Meli R., Plaz Torres M. C., Fanetti I., Orellana D., Zermiani P., Zuin M., De Bona A., D'Arminio Monforte A., Capretti A., Taddei M. T., Soncini M., Spinetti A., Zaltron S., Pigozzi M. G., Rossini A., Pan A., Dal Zoppo S., Zoncada A., Memoli M., Salpietro S., Hamid H., Messina E., Colombo A. E., Giglio O., Bonfanti P., Molteni C., Terreni N., Spinzi G., Conforti S., Clerici E., Menozzi F., Buscarini E., Centenaro R., Corbellini A., Noventa F., Gritti S., Giani P., Fabbiani, M, Lombardi, A, Colaneri, M, Del Poggio, P, Perini, P, D'Ambrosio, R, Degasperi, E, Dibenedetto, C, Giorgini, A, Pasulo, L, Maggiolo, F, Castelli, F, Brambilla, P, Spinelli, O, Re, T, Lleo, A, Rumi, M, Uberti-Foppa, C, Soria, A, Aghemo, A, Lampertico, P, Baiguera, C, Schiavini, M, Fagiuoli, S, Bruno, R, Borghi, M, Soffredini, R, Perbellini, R, Gori, A, Ferroni, V, Colpani, M, Manini, M, Cologni, G, Lazzaroni, S, Vinci, M, De Nicola, S, Mazzarelli, C, Angelini Zucchetti, T, Picciotto, V, Puoti, M, Rossotti, R, Landonio, S, Magni, C, Rizzardini, G, Colella, E, Columpsi, P, Gambaro, A, Spolti, A, Magnani, C, Vigano, P, Mena, M, Villa, M, Caramma, I, Basilico, C, Capelli, F, Biagiotti, S, Mazzone, A, Saladino, V, Baldacci, M, Gatti, F, Varalli, L, Morini, L, Menzaghi, B, Farinazzo, M, Meli, R, Plaz Torres, M, Fanetti, I, Orellana, D, Zermiani, P, Zuin, M, De Bona, A, D'Arminio Monforte, A, Capretti, A, Taddei, M, Soncini, M, Spinetti, A, Zaltron, S, Pigozzi, M, Rossini, A, Pan, A, Dal Zoppo, S, Zoncada, A, Memoli, M, Salpietro, S, Hamid, H, Messina, E, Colombo, A, Giglio, O, Bonfanti, P, Molteni, C, Terreni, N, Spinzi, G, Conforti, S, Clerici, E, Menozzi, F, Buscarini, E, Centenaro, R, Corbellini, A, Noventa, F, Gritti, S, Giani, P, Fabbiani M., Lombardi A., Colaneri M., Del Poggio P., Perini P., D'Ambrosio R., Degasperi E., Dibenedetto C., Giorgini A., Pasulo L., Maggiolo F., Castelli F., Brambilla P., Spinelli O., Re T., Lleo A., Rumi M., Uberti-Foppa C., Soria A., Aghemo A., Lampertico P., Baiguera C., Schiavini M., Fagiuoli S., Bruno R., Borghi M., Soffredini R., Perbellini R., Gori A., Ferroni V., Colpani M., Manini M., Cologni G., Lazzaroni S., Vinci M., De Nicola S., Mazzarelli C., Angelini Zucchetti T., Picciotto V., Puoti M., Rossotti R., Landonio S., Magni C. F., Rizzardini G., Colella E., Columpsi P., Gambaro A., Spolti A., Magnani C., Vigano P., Mena M., Villa M., Caramma I., Basilico C., Capelli F., Biagiotti S., Mazzone A., Saladino V., Baldacci M. P., Gatti F., Varalli L., Morini L., Menzaghi B., Farinazzo M., Meli R., Plaz Torres M. C., Fanetti I., Orellana D., Zermiani P., Zuin M., De Bona A., D'Arminio Monforte A., Capretti A., Taddei M. T., Soncini M., Spinetti A., Zaltron S., Pigozzi M. G., Rossini A., Pan A., Dal Zoppo S., Zoncada A., Memoli M., Salpietro S., Hamid H., Messina E., Colombo A. E., Giglio O., Bonfanti P., Molteni C., Terreni N., Spinzi G., Conforti S., Clerici E., Menozzi F., Buscarini E., Centenaro R., Corbellini A., Noventa F., Gritti S., and Giani P.

Abstract

In routine clinical practice, hepatitis C virus-infected patients can prematurely discontinue the prescribed regimen for several reasons. The aim of our study was to investigate sustained virological response (SVR12) rates in patients who prematurely discontinued directly acting antiviral (DAA) regimens and to assess the shortest effective duration of DAA able to lead to SVR12. We retrospectively collected the SVR rates of patients, registered in the NAVIGATORE-Lombardia Network database from January 2015, who discontinued DAAs before the predefined end of treatment. Overall, we included 365 patients, males were the majority (213, 58.4%), mean age was 60.5 years, and 53 (14.5%) patients were HIV-co-infected. Liver cirrhosis was observed in 251 (68.8%) subjects, and the most represented genotypes were 1b (n = 168, 46%) and 3 (n = 59, 16.2%). DAA was discontinued a median of 1 (IQR 1–4) weeks before the predefined EOT, with 164 (44.9%) patients stopping DAAs at least 2 weeks before the planned schedule. In patients with F0–F3 liver fibrosis, lower rates of SVR12 were observed in patients treated for <4 weeks: 50% (n = 2/4) vs. 99.1% (n = 109/110) for ≥4 weeks, p = 0.003. In patients with liver cirrhosis, lower rates of SVR12 were observed in patients treated <8 weeks: 83.3% (n = 25/30) vs. 94.6% (n = 209/221) for ≥8 weeks, p = 0.038. Despite premature discontinuation of DAA, high SVR12 rates were observed in a real-life setting for treatment lasting at least 4 weeks in patients with liver fibrosis F0–F3 and 8 weeks in those with liver cirrhosis. On this basis, feasibility of reducing DAA treatment duration should be explored in randomized clinical trials.

Published
2021

21. Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort

Author

Soria, A, Fava, M, Bernasconi, D, Lapadula, G, Colella, E, Valsecchi, M, Migliorino, G, D'Ambrosio, R, Landonio, S, Schiavini, M, Spinetti, A, Carriero, C, Degasperi, E, Cologni, G, Gatti, F, Vigano, P, Hasson, H, Uberti-Foppa, C, Pasulo, L, Baiguera, C, Rossotti, R, Vinci, M, Puoti, M, Giorgini, A, Menzaghi, B, Lombardi, A, Pan, A, Aghemo, A, Grossi, P, Boldizzoni, R, Colombo, S, Vigano, M, Rumi, M, Del Poggio, P, Valenti, L, Giglio, O, De Bona, A, d'Arminio Monforte, A, Colombo, A, Spinelli, O, Pigozzi, M, Molteni, C, Bonfanti, P, Terreni, N, Perini, P, Capretti, A, Bella, D, Liani, C, Polo, S, Aimo, G, Pagnucco, L, Bhoori, S, Centenaro, R, Graffeo, M, Ciaccio, A, Dionigi, E, Lazzaroni, S, Carderi, I, Di Marco, M, Rizzardini, G, Noventa, F, Lampertico, P, Fagiuoli, S, Soria A., Fava M., Bernasconi D. P., Lapadula G., Colella E., Valsecchi M. G., Migliorino G. M., D'Ambrosio R., Landonio S., Schiavini M., Spinetti A., Carriero C., Degasperi E., Cologni G., Gatti F., Vigano P., Hasson H., Uberti-Foppa C., Pasulo L., Baiguera C., Rossotti R., Vinci M., Puoti M., Giorgini A., Menzaghi B., Lombardi A., Pan A., Aghemo A., Grossi P. A., Boldizzoni R., Colombo S., Vigano M., Rumi M. G., Del Poggio P., Valenti L., Giglio O., De Bona A., d'Arminio Monforte A., Colombo A., Spinelli O., Pigozzi M. G., Molteni C., Bonfanti P., Terreni N., Perini P., Capretti A., Bella D., Liani C., Polo S., Aimo G., Pagnucco L., Bhoori S., Centenaro R., Graffeo M., Ciaccio A., Dionigi E., Lazzaroni S., Carderi I., Di Marco M., Rizzardini G., Noventa F., Lampertico P., Fagiuoli S., Soria, A, Fava, M, Bernasconi, D, Lapadula, G, Colella, E, Valsecchi, M, Migliorino, G, D'Ambrosio, R, Landonio, S, Schiavini, M, Spinetti, A, Carriero, C, Degasperi, E, Cologni, G, Gatti, F, Vigano, P, Hasson, H, Uberti-Foppa, C, Pasulo, L, Baiguera, C, Rossotti, R, Vinci, M, Puoti, M, Giorgini, A, Menzaghi, B, Lombardi, A, Pan, A, Aghemo, A, Grossi, P, Boldizzoni, R, Colombo, S, Vigano, M, Rumi, M, Del Poggio, P, Valenti, L, Giglio, O, De Bona, A, d'Arminio Monforte, A, Colombo, A, Spinelli, O, Pigozzi, M, Molteni, C, Bonfanti, P, Terreni, N, Perini, P, Capretti, A, Bella, D, Liani, C, Polo, S, Aimo, G, Pagnucco, L, Bhoori, S, Centenaro, R, Graffeo, M, Ciaccio, A, Dionigi, E, Lazzaroni, S, Carderi, I, Di Marco, M, Rizzardini, G, Noventa, F, Lampertico, P, Fagiuoli, S, Soria A., Fava M., Bernasconi D. P., Lapadula G., Colella E., Valsecchi M. G., Migliorino G. M., D'Ambrosio R., Landonio S., Schiavini M., Spinetti A., Carriero C., Degasperi E., Cologni G., Gatti F., Vigano P., Hasson H., Uberti-Foppa C., Pasulo L., Baiguera C., Rossotti R., Vinci M., Puoti M., Giorgini A., Menzaghi B., Lombardi A., Pan A., Aghemo A., Grossi P. A., Boldizzoni R., Colombo S., Vigano M., Rumi M. G., Del Poggio P., Valenti L., Giglio O., De Bona A., d'Arminio Monforte A., Colombo A., Spinelli O., Pigozzi M. G., Molteni C., Bonfanti P., Terreni N., Perini P., Capretti A., Bella D., Liani C., Polo S., Aimo G., Pagnucco L., Bhoori S., Centenaro R., Graffeo M., Ciaccio A., Dionigi E., Lazzaroni S., Carderi I., Di Marco M., Rizzardini G., Noventa F., Lampertico P., and Fagiuoli S.

Abstract

Background & Aims: In the direct-acting antiviral era, treatment of genotype-3 HCV (HCV-GT3) is still challenging. Real-life comparisons between recommended regimens, sofosbuvir (SOF)+daclatasvir (DAC), SOF/velpatasvir (VEL), glecaprevir/pibrentasvir (GLE/PIB), are scarce. We aimed at filling this data gap. Methods: Sustained virological response 12 weeks after treatment completion (SVR12) was assessed for all HCV-GT3 patients consecutively treated within the Lombardia web-based Navigatore HCV-Network; differences in SVR12 across regimens were evaluated by logistic regression. Results: Of the 2082 subjects with HCV-GT3, 1544 were evaluable for comparisons between regimens: SOF + DAC (1023, 66.2%), SOF/VEL (369, 23.9%), GLE/PIB (152, 9.8%). Patients treated with former regimens were more frequently male, cirrhotic, HIV-positive, pretreated, used ribavirin in their regimen, and had lower baseline HCV-RNA. SVR12 was similar across groups: 94.8% in SOF + DAC, 97.6% in SOF/VEL, 96.7% in GLE/PIB (P =.065). At univariate analysis, SVR12 was associated with female gender (97.9% vs 94.8%, P =.007) and lower median pretreatment Log10HCV-RNA (5.87 vs 6.20, P =.001). At multivariate logistic regression analysis, treatment with SOF/VEL was associated with a higher likelihood of SVR12 than SOF + DAC, but only in the absence of ribavirin (98% vs 90.3%). Female gender and lower pretreatment HCV-RNA were independently associated with SVR12. Conclusions: In a large real-life setting of HCV-GT3-infected patients with a high proportion of cirrhosis, the success rate was remarkable. The slight advantage of SOF/VEL on SOF + DAC was significant only without ribavirin. The current prescription shift towards novel regimens (ie SOF/VEL and GLE/PIB) in easier-to-treat patients allows ribavirin-free and shorter schedules without mining SVR12 in this <> genotype.

Published
2020

22. Safety of direct-acting antivirals for Hepatitis C infection and direct oral anticoagulants co-administration: an Italian multicentric study

Author

Rosato, V., Dallio, M., Federico, A., Spinetti, A., Ciancio, A., Milella, M., Colombatto, P., Brunetto, M., D'Adamo, G., Del Turco, E. Rosselli, Gallo, P., Falcomatà, A., Vespasiani-Gentilucci, U., De Nicola, S., Pugliese, N., Aghemo, A., D'Ambrosio, R., Lampertico, P., Soria, A.G., Colella, E., Mastrocinque, D., and Claar, E.

Published
2024
Full Text
View/download PDF

23. High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting

Author

Fabbiani M., Lombardi A., Colaneri M., Del Poggio P., Perini P., D'Ambrosio R., Degasperi E., Dibenedetto C., Giorgini A., Pasulo L., Maggiolo F., Castelli F., Brambilla P., Spinelli O., Re T., Lleo A., Rumi M., Uberti-Foppa C., Soria A., Aghemo A., Lampertico P., Baiguera C., Schiavini M., Fagiuoli S., Bruno R., Borghi M., Soffredini R., Perbellini R., Gori A., Ferroni V., Colpani M., Manini M., Cologni G., Lazzaroni S., Vinci M., De Nicola S., Mazzarelli C., Angelini Zucchetti T., Picciotto V., Puoti M., Rossotti R., Landonio S., Magni C. F., Rizzardini G., Colella E., Columpsi P., Gambaro A., Spolti A., Magnani C., Vigano P., Mena M., Villa M., Caramma I., Basilico C., Capelli F., Biagiotti S., Mazzone A., Saladino V., Baldacci M. P., Gatti F., Varalli L., Morini L., Menzaghi B., Farinazzo M., Meli R., Plaz Torres M. C., Fanetti I., Orellana D., Zermiani P., Zuin M., De Bona A., D'Arminio Monforte A., Capretti A., Taddei M. T., Soncini M., Spinetti A., Zaltron S., Pigozzi M. G., Rossini A., Pan A., Dal Zoppo S., Zoncada A., Memoli M., Salpietro S., Hamid H., Messina E., Colombo A. E., Giglio O., Bonfanti P., Molteni C., Terreni N., Spinzi G., Conforti S., Clerici E., Menozzi F., Buscarini E., Centenaro R., Corbellini A., Noventa F., Gritti S., Giani P., Fabbiani, Massimiliano, Lombardi, Andrea, Colaneri, Marta, Del Poggio, Paolo, Perini, Paolo, D'Ambrosio, Roberta, Degasperi, Elisabetta, Dibenedetto, Clara, Giorgini, Alessia, Pasulo, Luisa, Maggiolo, Franco, Castelli, Francesco, Brambilla, Paola, Spinelli, Ombretta, Tiziana, Re, Lleo, Ana, Rumi, Mariagrazia, Uberti-Foppa, Caterina, Soria, Alessandro, Aghemo, Alessio, Lampertico, Pietro, Baiguera, Chiara, Schiavini, Monica, Fagiuoli, Stefano, Bruno, Raffaele, Fabbiani, M, Lombardi, A, Colaneri, M, Del Poggio, P, Perini, P, D'Ambrosio, R, Degasperi, E, Dibenedetto, C, Giorgini, A, Pasulo, L, Maggiolo, F, Castelli, F, Brambilla, P, Spinelli, O, Re, T, Lleo, A, Rumi, M, Uberti-Foppa, C, Soria, A, Aghemo, A, Lampertico, P, Baiguera, C, Schiavini, M, Fagiuoli, S, Bruno, R, Borghi, M, Soffredini, R, Perbellini, R, Gori, A, Ferroni, V, Colpani, M, Manini, M, Cologni, G, Lazzaroni, S, Vinci, M, De Nicola, S, Mazzarelli, C, Angelini Zucchetti, T, Picciotto, V, Puoti, M, Rossotti, R, Landonio, S, Magni, C, Rizzardini, G, Colella, E, Columpsi, P, Gambaro, A, Spolti, A, Magnani, C, Vigano, P, Mena, M, Villa, M, Caramma, I, Basilico, C, Capelli, F, Biagiotti, S, Mazzone, A, Saladino, V, Baldacci, M, Gatti, F, Varalli, L, Morini, L, Menzaghi, B, Farinazzo, M, Meli, R, Plaz Torres, M, Fanetti, I, Orellana, D, Zermiani, P, Zuin, M, De Bona, A, D'Arminio Monforte, A, Capretti, A, Taddei, M, Soncini, M, Spinetti, A, Zaltron, S, Pigozzi, M, Rossini, A, Pan, A, Dal Zoppo, S, Zoncada, A, Memoli, M, Salpietro, S, Hamid, H, Messina, E, Colombo, A, Giglio, O, Bonfanti, P, Molteni, C, Terreni, N, Spinzi, G, Conforti, S, Clerici, E, Menozzi, F, Buscarini, E, Centenaro, R, Corbellini, A, Noventa, F, Gritti, S, and Giani, P

Subjects
Simeprevir, Male, medicine.medical_specialty, Cirrhosis, SVR, Sofosbuvir, Sustained Virologic Response, liver cirrhosis, antiviral treatment, Hepacivirus, Antiviral Agents, law.invention, Randomized controlled trial, law, Virology, Internal medicine, Medicine, Humans, chronic hepatitis C, Prospective cohort study, DAA, Retrospective Studies, Hepatology, liver cirrhosi, business.industry, Hepatitis C, Hepatitis C, Chronic, Middle Aged, medicine.disease, Discontinuation, Regimen, Infectious Diseases, Treatment Outcome, business, medicine.drug
Abstract

In routine clinical practice, hepatitis C virus-infected patients can prematurely discontinue the prescribed regimen for several reasons. The aim of our study was to investigate sustained virological response (SVR12) rates in patients who prematurely discontinued directly acting antiviral (DAA) regimens and to assess the shortest effective duration of DAA able to lead to SVR12. We retrospectively collected the SVR rates of patients, registered in the NAVIGATORE-Lombardia Network database from January 2015, who discontinued DAAs before the predefined end of treatment. Overall, we included 365 patients, males were the majority (213, 58.4%), mean age was 60.5years, and 53 (14.5%) patients were HIV-co-infected. Liver cirrhosis was observed in 251 (68.8%) subjects, and the most represented genotypes were 1b (n=168, 46%) and 3 (n=59, 16.2%). DAA was discontinued a median of 1 (IQR 1–4) weeks before the predefined EOT, with 164 (44.9%) patients stopping DAAs at least 2weeks before the planned schedule. In patients with F0–F3 liver fibrosis, lower rates of SVR12 were observed in patients treated for

Published
2021

25. 96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day vs triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluation

Author

Di Cristo V, Adorni F, Maserati R, Annovazzi Lodi M, Bruno G, Maggi P, Volpe A, Vitiello P, Abeli C, Bonora S, Ferrara M, Cossu MV, Oreni ML, Colella E, Rusconi S., Di Cristo, V, Adorni, F, Maserati, R, Annovazzi Lodi, M, Bruno, G, Maggi, P, Volpe, A, Vitiello, P, Abeli, C, Bonora, S, Ferrara, M, Cossu, Mv, Oreni, Ml, Colella, E, and Rusconi, S.

Published
2020

26. Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy

Author

Fabbiani, M., Borghetti, A., Squillace, N., Colafigli, M., Taramasso, L., Lombardi, A. (ORCID:0000-0002-9139-9269), Rossetti, B., Ciccullo, A., Colella, E., Picarelli, C., Berruti, M., Latini, A., Montagnani, F., Sambo, M., Di Biagio, A., Gori, A., Di Giambenedetto, S. (ORCID:0000-0001-6990-5076), Bandera, A., Fabbiani, M., Borghetti, A., Squillace, N., Colafigli, M., Taramasso, L., Lombardi, A. (ORCID:0000-0002-9139-9269), Rossetti, B., Ciccullo, A., Colella, E., Picarelli, C., Berruti, M., Latini, A., Montagnani, F., Sambo, M., Di Biagio, A., Gori, A., Di Giambenedetto, S. (ORCID:0000-0001-6990-5076), and Bandera, A.

Abstract

BACKGROUND: We explored predictors of CD4/CD8 ratio improvement and optimal immunological recovery (OIR) after initiation of antiretroviral therapy (ART) in naive people living with HIV (PLWH). METHODS: Retrospective multicenter study including naive PLWH starting ART with 2 nucleos(t)ide reverse transcriptase inhibitors + 1 integrase strand transfer inhibitor (InSTI) or non-NRTI or protease inhibitor (PI). PLWH were followed from the time of ART initiation (baseline) to the discontinuation of first-line regimen, virological failure, death, or loss to follow-up. Estimated incidence and predictors of time to CD4/CD8 ratio normalization (defined as ≥1) and OIR (defined as CD4/CD8 ratio ≥ 1 plus CD4 ≥ 500 cells/µL plus CD4% ≥ 30%) were explored by Kaplan-Meier curves and Cox regression analysis. RESULTS: Overall, 1428 PLWH (77.8% males, median age 39 years, 55.1% with positive cytomegalovirus (CMV) antibodies, median HIV-RNA 4.80 log copies/mL, median CD4 323 cells/µL, median CD4/CD8 ratio 0.32) were included, of which 21.5% (n = 307), 44.5% (n = 636), and 34% (n = 485) treated with InSTI-, PI-, and NNRTI-based regimens, respectively. The estimated proportion of CD4/CD8 normalization and OIR at 36 months was 38.6% and 32.9%, respectively. Multivariate analysis showed that InSTI-based regimens had a higher probability of CD4/CD8 ratio normalization and OIR both in the total population (P < 0.001 versus PI) and in advanced naive PLWH (P ≤ 0.001 versus PI and NNRTI). Moreover, subjects with positive CMV serology showed a lower probability of CD4/CD8 ratio normalization and OIR (P < 0.001). CONCLUSIONS: InSTI-based regimens showed a better immune recovery, suggesting that the type of first-line ART can influence immune reconstitution. PLWH with positive CMV serology showed an increased risk of suboptimal immune recovery.

Published
2021

27. HIV and SARS-CoV-2 Co-Infection: What are the Risks?

Author

Squillace, N, Ricci, E, Colella, E, Bonfanti, P, Squillace, Nicola, Ricci, Elena, Colella, Elisa, Bonfanti, Paolo, Squillace, N, Ricci, E, Colella, E, Bonfanti, P, Squillace, Nicola, Ricci, Elena, Colella, Elisa, and Bonfanti, Paolo

Abstract

The dramatic increase of the global pandemic of SARS-CoV-2 infection represents a critical issue that needs to be investigated to evaluate the associated risk factors for acquisition and worse outcome. The interplay between immune activation and immune depression during SARS-CoV-2 infection is an intriguing topic that still needs to be clarified. The role of HIV in SARS-CoV-2 infection is not well defined. Chronic inflammation linked to HIV infection could be a driver for a worse prognosis in people living with HIV (PLWH). We explored the role of HIV as a risk factor for SARS-CoV-2 infection and severity and which factors contributed to a worse prognosis when HIV infection was present. PubMed/MEDLINE was searched for "COVID-19" or "SARS-CoV2" and "HIV" or "AIDS" and ("hospitalization" or "intensive care" or "mechanical ventilation" or "death" OR "mortality"), both in MeSH and as free text in all fields. Our review focused on 21 studies that enrolled at least 40 PLWH. In most studies, HIV infection did not represent a risk factor for SARS-CoV-2 infection. On the contrary, the risk of severe COVID-19 and hospitalization was higher in PLWH. Low CD4 cell count consistently emerged as a risk factor for severe COVID-19. Comorbidities, either in people with or without HIV diagnosis, played a key role, especially because of their early development in PLWH.

Published
2021

28. HPV 16 and 18 contribute to development of anal dysplasia in HIV infection irrespective of gender and sexual orientation

Author

Squillace, N, Bernasconi, D, Lapadula, G, Soria, A, Sabbatini, F, Colella, E, Rossi, M, Tamburini, A, Leone, B, Brenna, A, Malandrin, S, Cavallero, A, Di Lucia, A, Braga, M, Bonfanti, P, Squillace, Nicola, Bernasconi, Davide Paolo, Lapadula, Giuseppe, Soria, Alessandro, Sabbatini, Francesca, Colella, Elisa, Rossi, Marianna, Tamburini, Andrea Marco, Leone, Biagio Eugenio, Brenna, Ambrogio, Malandrin, Sergio, Cavallero, Annalisa, Di Lucia, Adriana, Braga, Marco, Bonfanti, Paolo, Squillace, N, Bernasconi, D, Lapadula, G, Soria, A, Sabbatini, F, Colella, E, Rossi, M, Tamburini, A, Leone, B, Brenna, A, Malandrin, S, Cavallero, A, Di Lucia, A, Braga, M, Bonfanti, P, Squillace, Nicola, Bernasconi, Davide Paolo, Lapadula, Giuseppe, Soria, Alessandro, Sabbatini, Francesca, Colella, Elisa, Rossi, Marianna, Tamburini, Andrea Marco, Leone, Biagio Eugenio, Brenna, Ambrogio, Malandrin, Sergio, Cavallero, Annalisa, Di Lucia, Adriana, Braga, Marco, and Bonfanti, Paolo

Abstract

Objectives: The aim of the present study was too investigate prevalence and persistence of human papilloma virus (HPV) and cytological abnormalities (CAs) in the anal swabs of people living with HIV (PLWH): men who have sex with men (MSM), men who have sex with women (MSW) and women (W). Methods: Between March 2010 and January 2019, an anal swab for cytological and HPV genotyping tests was offered to all PLWH attending our clinic. Logistic regression analysis was conducted to identify predictors of infection. Results: In all, 354 PLWH were screened: 174 MSM, 90 MSW and 61 W. Prevalence of at least one high-risk (HR) HPV was higher in MSM (91%) and W (85%) than in MSW (77%) (P < 0.05). Cytological abnormalities were found in 21.1% of the entire population. At multivariable regression analysis a lower risk for HPV infection was found for W than for MSM [odds ratio = 0.24 (95% confidence interval: 0.115–0.513)] and for MSW than for MSM [0.37 (0.180–0.773)] and there was a significantly higher risk of CAs in PLWH with HPV 16 and 18 [3.3 (1.04–10.49)]. A total of 175 PLWH (103 MSM, 33 MSW and 26 W) had at least one follow-up visit (T1) after a median (interquartile range) follow-up of 3.6 (2.1–5.7) years. The acquisition rate of HR-HPV was high, with 66.7% of PLWH negative for HR-HPV at T0 who became positive at T1 (P < 0.001). The prevalence of CAs was stable (20.6%). A significant association between CAs at T1 and persistence of HPV-16 and/or 18 was found (P < 0.05). Conclusions: HPV 16 and 18 are associated with the presence and development of CAs irrespective of sexual orientation.

Published
2021

29. Caratteristiche di una coorte di pazienti con co-infezione HIV/HCV: i dati dell’Ambulatorio di Malattie Infettive dell’Ospedale San Gerardo di Monza

Author

Colella, E, Lapadula, G, Cogliandro, V, Rossi, M, Sabbatini, F, Soria, A, Squillace, N, Vitiello, P, Migliorino, G, Bonfanti, P, Colella, Elisa, Lapadula, Giuseppe, Cogliandro, Viola, Rossi, Marianna, Sabbatini, Francesca, Soria, Alessandro, Squillace, Nicola, Vitiello, Paola, Migliorino, Guglielmo Marco, Bonfanti, Paolo, Colella, E, Lapadula, G, Cogliandro, V, Rossi, M, Sabbatini, F, Soria, A, Squillace, N, Vitiello, P, Migliorino, G, Bonfanti, P, Colella, Elisa, Lapadula, Giuseppe, Cogliandro, Viola, Rossi, Marianna, Sabbatini, Francesca, Soria, Alessandro, Squillace, Nicola, Vitiello, Paola, Migliorino, Guglielmo Marco, and Bonfanti, Paolo

Abstract

Last epidemiological data show a decreasing trend of HCV infection prevalence in the general population; these data seem to be confirmed also in ICONA of HIV-positive patients. However, it is well known that prevalence data present many, and sometimes important, fluctuations depending on local epidemiology. We studied HCV infection characteristics in our 1974 HIV-positive patients cohort. The HIV/HCV co-infection prevalence was 19% (371 patients); 79% (294) of them were male sex; nationality was Italian in 94% (248) of patients; principal risk factor resulted to be intravenous drug use (IVDU) (162, 44%); average age was 52.8 years (standard deviation 8.6). 65% (241) of patients had detectable HCV-RNA at diagnosis, while, considering 262 patients who are still actively followed, 92% (240) of them have reached sustained virologic response (SVR). The high prevalence of eradication in our setting of HIV/ HCV co-infected patients could suggest micro-elimination as a possible solving approach to eradicate HCV infection. However, retention in care continues to be an important challenge and a scope for improvement of HIV-positive and HIV/HCV co-infected patient management.

Published
2020

30. Bibliography

Author

Shook, John R., primary, Colella, E. Paul, additional, Friedman, Lesley, additional, Ryan, Frank X., additional, and Skrupskelis, Ignas K., additional

Published
1998
Full Text
View/download PDF

31. Preliminary Material

Author

Shook, John R., primary, Colella, E. Paul, additional, Friedman, Lesley, additional, Ryan, Frank X., additional, and Skrupskelis, Ignas K., additional

Published
1998
Full Text
View/download PDF

33. Introduction

Author

Shook, John R., primary, Colella, E. Paul, additional, Friedman, Lesley, additional, Ryan, Frank X., additional, and Skrupskelis, Ignas K., additional

Published
1998
Full Text
View/download PDF

34. Subject Index

Author

Shook, John R., primary, Colella, E. Paul, additional, Friedman, Lesley, additional, Ryan, Frank X., additional, and Skrupskelis, Ignas K., additional

Published
1998
Full Text
View/download PDF

35. Research Methods

Author

Shook, John R., primary, Colella, E. Paul, additional, Friedman, Lesley, additional, Ryan, Frank X., additional, and Skrupskelis, Ignas K., additional

Published
1998
Full Text
View/download PDF

36. Value Inquiry Book Series

Author

Shook, John R., primary, Colella, E. Paul, additional, Friedman, Lesley, additional, Ryan, Frank X., additional, and Skrupskelis, Ignas K., additional

Published
1998
Full Text
View/download PDF

37. Author Index

Author

Shook, John R., primary, Colella, E. Paul, additional, Friedman, Lesley, additional, Ryan, Frank X., additional, and Skrupskelis, Ignas K., additional

Published
1998
Full Text
View/download PDF

38. Acknowledgments

Author

Shook, John R., primary, Colella, E. Paul, additional, Friedman, Lesley, additional, Ryan, Frank X., additional, and Skrupskelis, Ignas K., additional

Published
1998
Full Text
View/download PDF

41. Hepatitis C virus-related factors associated WITH cognitive performance in HIV-HCV-coinfected patients

Author

Fabbiani, M, Ciccarelli, N, Castelli, V, Soria, A, Borghetti, A, Colella, E, Moschese, D, Valsecchi, M, Emiliozzi, A, Gori, A, De Luca, A, Bandera, A, Di Giambenedetto, S, Ciccarelli, N (ORCID:0000-0002-7582-9142), De Luca, A (ORCID:0000-0002-8311-6935), Di Giambenedetto, S (ORCID:0000-0001-6990-5076), Fabbiani, M, Ciccarelli, N, Castelli, V, Soria, A, Borghetti, A, Colella, E, Moschese, D, Valsecchi, M, Emiliozzi, A, Gori, A, De Luca, A, Bandera, A, Di Giambenedetto, S, Ciccarelli, N (ORCID:0000-0002-7582-9142), De Luca, A (ORCID:0000-0002-8311-6935), and Di Giambenedetto, S (ORCID:0000-0001-6990-5076)

Abstract

The contribution of HCV-related variables to cognitive impairment in HIV-HCV-coinfected patients has been poorly investigated. We selected HIV-HCV-coinfected patients undergoing cognitive examination (exploring memory, language, speed of mental processing and fine motor function) at three clinical centres. Cognitive performance was evaluated using Z-transformed scores. Logistic regression analysis was used to investigate variables associated to cognitive impairment (defined as a composite Z-score <= - 1). Overall, 146 HIV-HCV-coinfected patients were enrolled. Median HCV-RNA was 6.2logU/mL. HCV genotype 1a/b was the most represented (53.4%). Liver fibrosis was mild (Fib4 <= 1.45) in the majority of patients (44.5%). Global cognitive impairment was diagnosed in 35 (24%) subjects. Exploring each domain, a higher proportion of impairment was observed for memory (37%) followed by speed of mental processing (32.2%), fine motor functioning (24%) and language (18.5%). Among HCV-related variables, the duration of HCV infection was independently associated with global cognitive impairment (aOR 1.13 per +1 year, p = 0.016) and abnormal speed of mental processing (aOR 1.16 per +1 year, p = 0.001), while higher HCV-RNA was independently associated to fine motor functioning impairment (aOR 1.98 per +1log, p = 0.037). HCV genotype, fibrosis stage, transaminases or bilirubin levels were not related to cognitive performance. Of note, integrase inhibitor (InSTI) use was independently associated to a pathological performance in fine motor functioning (aOR 3.34, p = 0.035) and memory (aOR 3.70, p = 0.014). In conclusion, the duration of HCV infection and HCV-RNA load showed an association with cognitive impairment, suggesting a role of hepatitis-related factors in the development of cognitive disorders in HIV-HCV-coinfected patients. The association between InSTI use and altered cognitive performance should prompt investigations about potential neurotoxicity of these drugs.

Published
2019

50. CHAPTER 5: Two Faces of Italian Pragmatism: The Prezzolini-Calderoni Debate, 1904-1905.

Author

Colella, E. Paul

Subjects
*PRAGMATISM
Abstract

Chapter 5 of the book "The Italian Pragmatists: Between Allies and Enemies" by Giovanni Maddalena and Giovanni Tuzet is presented. It discusses about the two faced Italian pragmatists and William James meeting with the young followers in Rome and to his surprise the people were divided over the idea of pragmatism. It highlights the birth of Giuliano il Sofista, discusses about The Prezzolini-Calderoni 1904-1905 Debate, and the conflict of the positivist.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results